vTv Therapeutics Inc. (NASDAQ:VTVT – Get Free Report) was the recipient of a large drop in short interest in the month of February. As of February 28th, there was short interest totalling 24,100 shares, a drop of 13.6% from the February 13th total of 27,900 shares. Approximately 1.6% of the shares of the stock are short sold. Based on an average daily volume of 13,300 shares, the short-interest ratio is presently 1.8 days.
vTv Therapeutics Stock Performance
NASDAQ VTVT opened at $20.99 on Wednesday. vTv Therapeutics has a 52-week low of $12.12 and a 52-week high of $30.99. The company has a market capitalization of $66.96 million, a P/E ratio of -4.63 and a beta of 1.07. The company has a fifty day moving average of $16.76 and a 200-day moving average of $15.40.
Institutional Trading of vTv Therapeutics
Hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC lifted its stake in vTv Therapeutics by 12.9% in the fourth quarter. Geode Capital Management LLC now owns 11,634 shares of the biotechnology company’s stock worth $158,000 after purchasing an additional 1,327 shares during the last quarter. JPMorgan Chase & Co. bought a new stake in vTv Therapeutics in the fourth quarter worth $25,000. Finally, FMR LLC bought a new stake in vTv Therapeutics in the third quarter worth $2,402,000. 17.51% of the stock is owned by institutional investors.
Analyst Ratings Changes
Read Our Latest Stock Analysis on VTVT
vTv Therapeutics Company Profile
vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.
Featured Articles
- Five stocks we like better than vTv Therapeutics
- What Are Dividend Contenders? Investing in Dividend Contenders
- Arqit Stock Soars as NVIDIA’s GTC Fuels Quantum Excitement
- Roth IRA Calculator: Calculate Your Potential Returns
- 3 Must-Own Stocks to Build Wealth This Decade
- How to trade penny stocks: A step-by-step guide
- Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.